



Information Sheet for Hillingdon Scrutiny Committee 12th April 2017

M12 Clinical Quality Report

NHS Improvement - Single Oversight Framework								
Clostridium difficile	M12 1			Performance Standard Dept. Health Trajectory = 23	Variance from Threshold -23 YTD			
MRSA Bacteraemia	M12 YTD M12 0 0			Zero tolerance	0 cases reported to PHE for M12			
Indicator	M12			M12 Target	Variance from Target / Trajectory M12 Position			
18 weeks RTT Incomplete	92.66%			M12 Trajectory = 92.58%	+0.08%			
52 week breaches	0			Zero tolerance	Zero breaches for M12			
Number of diagnostic tests waiting 6 weeks+ (%)	0%			1%	1% target met for M12			
Cancer - 62 day Urgent GP referral to first definitive treatment	14 patients 46.67%			M12 Trajectory = 65.00%	-18.33%			
Cancer - 62 day Urgent GP referral to first definitive treatment - shadow reporting	14 patients 60.00%		ts	M12 Trajectory = 65.00%	-5.00%			
VTE Risk assessments	Q3 = 96.04		4	95%	Target met for Q3			

NHS England - NHS Standard Contract								
Urgent operations cancelled for the 2nd time		0	Zero tolerano	Zero breaches for M12				
Cancelled Operations; not carried out within 28 days		1	Zero tolerance of no readmiss	One breach for M12				
Cancelled Procedures; (Catheter Labs, Transplant Assessment and Bronchoscopy Suite); not carried out within 28 days		0	Zero tolerance of no readmiss	Zero breaches for M12				
Cancer – 14 day Urgent GP Referral	No. of ca	ases M12 2016/17 = 1 100%	93%	Target met for M12				
Cancer – 31 day 1st treatment		27 patients 100%	96%	Target met for M12				
Cancer – 31 day subsequent treatment		26 patients 96.15%	94%	Target met for M12				
Incidents								
	16/17 M12 15/16 Total Incidents 15/16		15/16 YTD Incidents at M12	/16 YTD Incidents at M12 16/17 YTD Incidents		Δ		
Outbreaks of Infection	0 2		2 4			+2		
Serious Incidents	0 24		24 11			-13		
Never Events	0	0	0			0		



NHSI Single Oversight Framework: 7th April 2017 update

The first full segmentation was published on 14th December 2016. This followed the 'shadow' segmentation published in October 2016 which provided an indicative outline of providers' support needs.

The segmentation was updated on 7th April 2017. Royal Brompton & Harefield NHS Foundation Trust continues to be in segment 2.

Organisation Name	Sector	Region Name	Segment
Royal Brompton & Harefield NHS Foundation Trust	Specialist	London	2



CQC Inspection Report

Our ratings for Harefield Hospital

	Safe	Effective	Caring	Responsive	Well-led	Overall
Medicalcare	Good	Good	Good	Good	Good	Good
Surgery	Requires improvement	☆ Outstanding	Outstanding	Good	Good	Good
Critical care	Good	Good	Good	Good	Good	Good
End of life care	Good	Good	Good	Good	Good	Good
Outpatients and diagnostic imaging	Good	N/A	Good	Requires improvement	Good	Good
Overall	Good	Good	Good	Good	Good	Good

Our ratings for Royal Brompton Hospital

	Safe	Effective	Caring	Responsive	Well-led	Overall
Medicalcare	Good	Outstanding	Good	Good	Outstanding	Outstanding
Surgery	Requires improvement	Good	Good	Requires improvement	Requires improvement	Requires improvement
Critical care	Requires improvement	Good	Good	Good	Requires improvement	Requires improvement
Services for children and young people	Good	Good	Good	Good	Outstanding	Good
End of life care	Good	Requires improvement	Good	Good	Good	Good
Outpatients and diagnostic imaging	Good	N/A	Good	Requires improvement	Good	Good
Overall	Requires improvement	Good	Good	Requires improvement	Requires improvement	Requires improvement

Our ratings for Royal Brompton and Harefield NHS Foundation Trust

	Safe	Effective	Caring	Responsive	Well-led	Overall
Overall	Requires improvement	Good	Good	Requires improvement	Good	Requires improvement